Ruan Xiulu, Tadia Riaz, Couch J Patrick, Ruan Jingchun, Chiravuri Srinivas
Physicians Pain Specialists of Alabama, Mobile, AL, USA.
Pain Physician. 2008 May-Jun;11(3):363-7.
Intraspinal drug delivery therapy has been increasingly used in patients with intractable, nonmalignant pain who fail to respond to conventional treatment or cannot tolerate systemic opioid therapy due to side effects. By infusing small amount of analgesics directly into the cerebrospinal fluid in close proximity to the receptor sites in the spinal cord, one is able to achieve the spinally mediated analgesia, sparing side effects due to systemic opioids. Prior to permanent intraspinal pump implantation, an intraspinal opioid screening trial is required to document the efficacy of intraspinal opioid for analgesia. Although there are a few approaches in conducting such screening trials, a patient controlled continuous epidural morphine infusion trial, performed in an outpatient setting, is widely accepted by many interventional pain specialists. The major advantage of conducting an outpatient trial is that it mimics what patients do in their daily living, therefore minimizing the false positive rate.
To report a case of severe peripheral edema observed during an outpatient continuous epidural morphine infusion trial.
A 64-year-old female, with a 7-year history of severe low back pain and bilateral leg pain due to failed back surgery syndrome, was referred to our clinic for intraspinal drug delivery therapy after failing to respond to conservative treatment, including a previous history of 3 lumbosacral surgeries. Following a pre-implantation psychological evaluation confirming her candidacy, she underwent an outpatient patient-controlled continuous epidural morphine trial. A tunneled lumbar epidural catheter was placed at L2-L3 with catheter tip advanced to T12 under fluoroscopic guidance. Satisfactory catheter placement was confirmed by epidurogram. The proximal tip of the catheter was then tunneled, subcutaneously and connected to a Microject PCEA pump (Codman, Raynham, MA, USA) and reservoir bag containing preservative-free morphine 0.5 mg/mL. The pump was programmed to deliver a basal rate of 0.5 mL/hr. The bolus dose was 0.2 mL with 60 minute lock-out interval. The patient was instructed how to operate the infusion pump before discharging home. During the following 2 weeks, she reported more than 90% reduction of her low back and leg pain. She only had to use the on-demand bolus doses averaging 2 - 3 times a day. She was able to wean off her oral opioids completely. However, she developed bilateral leg edema and gained over 12 pounds during the 2-week infusion trial, despite wearing elastic stockings and keeping her legs elevated whenever possible. She did not experience any other significant side effects. Her edema finally resolved 2 days after termination of the epidural infusion.
Peripheral edema may occur and persist during epidural morphine infusion. This report represents the first case report, to the best of our knowledge, describing severe peripheral edema in an otherwise healthy patient while on epidural morphine administration during an outpatient epidural morphine infusion trial. This case report shows that continuous epidural morphine infusion, even in small dose, may cause peripheral edema in some patients.
脊髓内药物输送疗法越来越多地用于患有顽固性非恶性疼痛的患者,这些患者对传统治疗无反应或因副作用而无法耐受全身性阿片类药物治疗。通过将少量镇痛药直接注入脊髓中靠近受体部位的脑脊液中,能够实现脊髓介导的镇痛,避免全身性阿片类药物引起的副作用。在永久性植入脊髓泵之前,需要进行脊髓阿片类药物筛选试验以证明脊髓阿片类药物的镇痛效果。虽然进行此类筛选试验有几种方法,但在门诊环境中进行的患者自控连续硬膜外吗啡输注试验被许多介入疼痛专家广泛接受。进行门诊试验的主要优点是它模拟了患者在日常生活中的行为,因此将假阳性率降至最低。
报告在门诊连续硬膜外吗啡输注试验期间观察到严重外周水肿的一例病例。
一名64岁女性,因腰椎手术失败综合征导致严重腰痛和双侧腿痛7年,在对包括3次腰骶部手术史在内的保守治疗无反应后,被转诊至我院接受脊髓内药物输送治疗。在植入前的心理评估确认她符合条件后,她接受了门诊患者自控连续硬膜外吗啡试验。在透视引导下,于L2-L3置入一根经隧道的腰椎硬膜外导管,导管尖端推进至T12。硬膜外造影证实导管位置满意。然后将导管近端经皮下隧道引出,并连接至一个Microject PCEA泵(美国马萨诸塞州雷纳姆市科德曼公司生产)和一个装有0.5mg/mL无防腐剂吗啡的储药袋。泵被设定为以0.5mL/小时的基础速率给药。推注剂量为0.2mL,锁定时间间隔为60分钟。在患者出院前指导其如何操作输注泵。在接下来的2周内,她报告腰腿痛减轻了90%以上。她每天仅需平均使用2 - 3次按需推注剂量。她能够完全停用口服阿片类药物。然而,在为期2周的输注试验期间,尽管她穿着弹力袜并尽可能抬高双腿,但仍出现了双侧腿部水肿,体重增加超过12磅。她未经历任何其他明显的副作用。硬膜外输注终止2天后,她的水肿最终消退。
硬膜外输注吗啡期间可能会出现并持续外周水肿。据我们所知,本报告是首例描述在门诊硬膜外吗啡输注试验期间接受硬膜外吗啡治疗的健康患者出现严重外周水肿的病例报告。该病例报告表明,即使是小剂量的连续硬膜外吗啡输注,在某些患者中也可能导致外周水肿。